التفاصيل البيبلوغرافية
| العنوان: |
Association of Somatic TET2 Mutations With Giant Cell Arteritis. |
| المؤلفون: |
Robinette, Michelle L., Weeks, Lachelle D., Kramer, Ryan J., Agrawal, Mridul, Gibson, Christopher J., Yu, Zhi, Sekar, Aswin, Mehta, Arnav, Niroula, Abhishek, Brown, Jared T., McDermott, Gregory C., Reshef, Edith R., Lu, Jonathan E., Liou, Victor D., Chiou, Carolina A., Natarajan, Pradeep, Freitag, Suzanne K., Rao, Deepak A., Ebert, Benjamin L. |
| المصدر: |
Arthritis & Rheumatology; Mar2024, Vol. 76 Issue 3, p438-443, 6p |
| مصطلحات موضوعية: |
BLOOD testing, RESEARCH, GENETIC mutation, SEQUENCE analysis, TISSUE banks, GIANT cell arteritis, ACQUISITION of data, RISK assessment, GENOMES, MEDICAL records, HEMATOLOGIC malignancies, RESEARCH funding, HEMATOPOIESIS, STATISTICAL correlation, ELECTRONIC health records, ODDS ratio, PROPORTIONAL hazards models, PHENOTYPES, DISEASE risk factors |
| مصطلحات جغرافية: |
UNITED Kingdom |
| مستخلص: |
Objective: Giant cell arteritis (GCA) is an age‐related vasculitis. Prior studies have identified an association between GCA and hematologic malignancies (HMs). How the presence of somatic mutations that drive the development of HMs, or clonal hematopoiesis (CH), may influence clinical outcomes in GCA is not well understood. Methods: To examine an association between CH and GCA, we analyzed sequenced exomes of 470,960 UK Biobank (UKB) participants for the presence of CH and used multivariable Cox regression. To examine the clinical phenotype of GCA in patients with and without somatic mutations across the spectrum of CH to HM, we performed targeted sequencing of blood samples and electronic health record review on 114 patients with GCA seen at our institution. We then examined associations between specific clonal mutations and GCA disease manifestations. Results: UKB participants with CH had a 1.48‐fold increased risk of incident GCA compared to UKB participants without CH. GCA risk was highest among individuals with cytopenia (hazard ratio [HR] 2.98, P = 0.00178) and with TET2 mutation (HR 2.02, P = 0.00116). Mutations were detected in 27.2% of our institutional GCA cohort, three of whom had HM at GCA diagnosis. TET2 mutations were associated with vision loss in patients with GCA (odds ratio 4.33, P = 0.047). Conclusions: CH increases risk for development of GCA in a genotype‐specific manner, with the greatest risk being conferred by the presence of mutations in TET2. Somatic TET2 mutations likewise increase the risk of GCA‐associated vision loss. Integration of somatic genetic testing in GCA diagnostics may be warranted in the future. [ABSTRACT FROM AUTHOR] |
|
Copyright of Arthritis & Rheumatology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
